Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Covid symbols : Vxrt save search
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
Published: 2022-02-24 (Crawled : 13:30) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -9.93%
H: 0.0%
C: 0.0%
covid-19 react system covid response active pons vaccine
Vaxart to Test Cross-Reactivity of its COVID-19 Oral Tablet Vaccine Against Omicron
Published: 2021-12-16 (Crawled : 15:00) - biospace.com/
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 0.62%
H: 4.13%
C: 0.92%
covid-19 covid test vaccine
Vaxart Announces Publication of Complete Data from Preclinical COVID-19 Oral Vaccine Hamster Challenge Study in Journal of Infectious Diseases
Published: 2021-11-16 (Crawled : 13:30) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -3.34%
H: 0.0%
C: 0.0%
covid disease preclinical infectious disease vaccine pre-clinical
Vaxart Doses First Subject in Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
Published: 2021-10-26 (Crawled : 13:00) - biospace.com/
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 1.16%
H: 0.0%
C: 0.0%
covid vaccine trial covid-19
New Duke University-led Study Shows That Vaxart's Oral COVID-19 Vaccine Candidate Reduces Airborne Transmission of SARS-CoV-2 Infection in Animal Model
Published: 2021-10-07 (Crawled : 22:00) - biospace.com/
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -0.14%
H: 3.24%
C: 0.0%
covid vaccine injection sars-cov-2 infections
Vaxart Begins Recruiting in Global Phase II COVID-19 Oral Tablet Vaccine Clinical Trial
Published: 2021-10-06 (Crawled : 13:00) - biospace.com/
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -2.05%
H: 2.38%
C: -0.7%
covid vaccine trial covid-19
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
Published: 2021-08-02 (Crawled : 13:00) - biospace.com/
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 4.19%
H: 3.05%
C: -2.56%
covid fda vaccine fda clearance application covid-19
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity against Other Coronaviruses
Published: 2021-05-03 (Crawled : 21:00) - globenewswire.com
EBS | $1.86 -2.11% -1.61% 1.1M
|
Health Technology
|
| O: -1.2%
H: 0.62%
C: -2.88%
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 18.45%
H: 0.53%
C: -7.79%
covid vaccine
Vaxart to Host a Key Opinion Leader Webinar on the Importance of T-Cell Responses for COVID-19 Vaccines
Published: 2021-04-26 (Crawled : 12:00) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 2.16%
H: 7.04%
C: 6.69%
covid vaccine t-cell response
Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
Published: 2021-04-22 (Crawled : 13:00) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 6.46%
H: 3.54%
C: -2.87%
covid vaccine
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Published: 2021-02-03 (Crawled : 14:01) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -53.56%
H: 17.58%
C: -9.09%
covid positive vaccine trial phase 3 phase 1 phase 2
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication
Published: 2021-01-26 (Crawled : 14:01) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 6.67%
H: 0.84%
C: -12.5%
covid vaccine preclinical covid-19 pre-clinical
Vaxart, Inc. Appoints New CEO to Accelerate Advancement of COVID-19 and Other Programs
Published: 2020-06-15 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -3.0%
H: 9.73%
C: 8.85%
covid new ceo ceo leo covid-19 program
Vaxart’s COVID-19 Vaccine Selected for the U.S. Government’s Operation Warp Speed
Published: 2020-06-26 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 83.55%
H: 24.46%
C: -30.03%
covid vaccine covid-19
Vaxart Announces IND Filed for COVID-19 Vaccine
Published: 2020-08-10 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 4.57%
H: 2.6%
C: -2.24%
covid vaccine covid-19
Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies
Published: 2020-09-08 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 12.37%
H: 2.71%
C: -13.0%
covid vaccine preclinical response covid-19 pre-clinical
Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program
Published: 2020-09-14 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 20.38%
H: 32.76%
C: 21.94%
covid fda clearance fda vaccine covid-19 application clearance
Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine
Published: 2020-10-13 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 5.11%
H: 13.77%
C: 3.51%
covid vaccine trial phase 3 phase 1 phase 2
Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine
Published: 2020-10-14 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: -0.78%
H: 2.1%
C: -9.33%
covid positive vaccine covid-19
Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine
Published: 2020-11-12 (Crawled : 09:36) - globenewswire.com
VXRT | $0.836 -3.48% -3.6% 880K
|
Health Technology
|
| O: 12.7%
H: 8.86%
C: 2.31%
covid vaccine covid-19
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.